Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Neurology
•
Neuromuscular
•
Neurohospitalist
How do you treat checkpoint inhibitor induced myasthenia gravis?
Is recurrence treated differently?
Related Questions
Should IVIG dosing in patients with autoimmune disease (i.e., dermatomyositis) who become pregnant continue to be based on actual weight at the time of each infusion, or should it be limited to pre-pregnancy weight?
How do you approach weaning treatments for CIDP in remission?
What treatments, after appropriate dose reductions/delays, do you offer for patients with oxaliplatin-induced cold allodynia/dysesthesia?
When would you consider testing for LGI1 antibodies in patients with unexplained neuropathic pain?
When do you test for myasthenia antibodies beyond AChR and MuSK?
How do you counsel patients who wish to travel to high altitudes with myasthenia gravis?
What leads you to suspect that a foot drop is secondary to a myopathy rather than a neuropathic process?
How would one approach treating a patient with primary immunodeficiency on IVIG treatment who develops myasthenia gravis?
Do you always biopsy patients who present with classic skin findings of dermatomyositis?
How do you use serum IgG levels when treating with FcRN inhibitors?
